BridgeBio Pharma (BBIO) Total Debt (2018 - 2026)

BridgeBio Pharma's Total Debt history runs 9 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Total Debt changed N/A year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (changed N/A YoY), while the FY2025 annual figure was $564.6 million, up 3.56% from the prior year.
• Total Debt came in at $1.3 billion for Q1 2026 at BridgeBio Pharma, up from $564.6 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.3 billion in Q1 2026 to a low of $418.4 million in Q2 2022.
• A 5-year average of $527.7 million and a median of $436.2 million in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 359.83% in 2022 and declined 1.25% in 2024, its largest moves.
• BridgeBio Pharma's Total Debt stood at $431.0 million in 2022, then advanced by 3.59% to $446.4 million in 2023, then increased by 22.11% to $545.2 million in 2024, then advanced by 3.56% to $564.6 million in 2025, then soared by 128.3% to $1.3 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $1.3 billion, $564.6 million, and $740.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison